Every 10-Q that Aligos Therapeutics, Inc. (ALGS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALGS filings page.
Aligos Therapeutics reported Q2 2026 results marked by its first substantial licensing revenue but continued operating losses and a short cash runway. Revenue was driven by $27.8 million from a new license agreement with Xiamen Amoytop Biotech for pevifoscorvir sodium in Greater China; there was no Q2 customer collaboration revenue. Operating expenses rose to $29.7 million, including $24.1 million of research and development as the Phase 2 B‑SUPREME trial for pevifoscorvir sodium ramped, while general and administrative costs were stable at $5.6 million.
Q2 loss from operations was $1.9 million, and after a $3.0 million non‑cash gain from remeasuring 2023 Common Warrants and a $2.8 million tax provision tied largely to Amoytop withholding taxes, the net loss was $1.5 million (basic and diluted loss per share of $0.14). For the first six months of 2026, the company recorded a net loss of $24.5 million on operating cash outflows of $48.1 million.
Cash and cash equivalents were $30.4 million at June 30, 2026, with no short‑term investments outstanding and $27.8 million in accounts receivable from the Amoytop license. Management states that existing cash plus the $25.0 million net upfront received from Amoytop in July 2026 are expected to fund planned operations only into the fourth quarter of 2026, which raises substantial doubt about the company’s ability to continue as a going concern absent additional capital. The pipeline advanced, with regulatory designations and ongoing studies in chronic hepatitis B and MASH, but development remains in clinical stages with no product sales.
Aligos Therapeutics reported Q1 2026 results with revenue from customers of $2.8 million, driven mainly by a milestone under its Amoytop collaboration, and a net loss of $23.0 million.
The company spent $23.4 million on research and development and $6.4 million on general and administrative expenses, reflecting ramp-up of its Phase 2 B‑SUPREME trial for HBV candidate pevifoscorvir sodium. Cash, cash equivalents and short‑term investments totaled $54.9 million as of March 31, 2026.
Management states that existing cash, including an expected $25 million upfront payment from a new Greater China license with Amoytop for pevifoscorvir sodium, will fund operations into the fourth quarter of 2026. Because this runway extends for less than one year from the filing date, recurring losses and negative operating cash flows have raised substantial doubt about Aligos’ ability to continue as a going concern without additional capital.
The new Amoytop license grants exclusive HBV rights in Greater China and could provide up to $420 million in milestones plus tiered high single‑digit royalties, while Aligos retains rights in the US, Europe and other major markets. Key clinical programs include pevifoscorvir sodium for chronic HBV, ALG‑055009 for MASH and obesity, and ALG‑097558 for coronavirus infections.
Aligos Therapeutics (ALGS) filed its quarterly report for the period ended September 30, 2025. The company reported a Q3 net loss of $31.5 million on $0.7 million in revenue from customers, driven by research and development expenses of $23.9 million and general and administrative costs of $5.2 million. A non‑cash change in fair value of 2023 common warrants reduced the warrant liability to $13.4 million as of September 30, 2025.
Liquidity improved after a February 2025 PIPE that generated gross proceeds of $105.0 million (net $101.4 million). Cash, cash equivalents and short‑term investments were $99.1 million as of September 30, 2025. Management states these resources are expected to fund operations into the third quarter of 2026 and indicates substantial doubt about the ability to continue as a going concern absent additional financing.
As of October 31, 2025, shares outstanding were 6,153,582, comprised of 5,353,582 voting and 800,000 non‑voting shares. There were 4,217,432 pre‑funded warrants outstanding as of October 31, 2025 that are immediately exercisable, subject to beneficial ownership limitations.
Aligos Therapeutics (ALGS) Q2-25 Form 10-Q shows a capital-strengthening quarter driven by its February 2025 $105 million PIPE financing. Net proceeds of $101.4 million and the re-measurement of 2023 warrants (-$63.2 million liability) swung stockholders’ equity from a $(29.0) million deficit at 12/31/24 to $101.9 million at 6/30/25. Shares outstanding rose to 6.15 million (post 1-for-25 split).
Liquidity: Cash & cash equivalents fell to $18.7 million, but short-term U.S. Treasury holdings increased to $104.3 million, lifting total liquid resources to $122.9 million. Management states this provides >12-month runway.
Operations: The company remains pre-commercial. Customer revenue was $1.3 million YTD (-27% YoY) tied to Amoytop R&D services. Six-month R&D expense fell 24% YoY to $28.5 million; G&A dropped 19% to $10.6 million. Operating loss narrowed to $37.8 million (vs. $48.5 million). However, after the warrant fair-value gain and $2.1 million interest income, YTD net income reached $27.2 million (prior-year loss $29.8 million).
Cash flow: OCF was -$36.4 million; capex minimal. Financing inflow of $101.6 million (PIPE & ESPP) offset $83.5 million deployed into Treasuries.
- 2025 PIPE issued 2.10 million shares, 1.92 million pre-funded warrants and 2.01 million common warrants (exercise $26.02; expiry 2032).
- Authorized share cap raised to 100 million voting and 15.8 million non-voting shares.
- Phase 2 CAM-E candidate ALG-000184 B-SUPREME trial has begun enrollment; interim read-out expected 2026.
Outlook: Aligos projects current cash to fund ≥12 months of R&D. Future value hinges on clinical read-outs and additional financings; no commercial revenue is expected near term.